← Leaderboards
Zhongzhi Wu
Seak Therapeutics, Llc
$554,805
Attributed
$754,787
Total exposure
2
Grants
2
Lead (contact PI)
Attributed= this PI's even-split share of every grant they're on (the fair, additive number). Exposure = full size of all those grants.
Funding over time
peak $455K · FY2019–20$500K$375K$250K$125K$0
'19
'20
Funding mix
By agency
NIH$754,787 · 2
By mechanism
R43$754,787 · 2
Top collaborators
- Wei Li1 shared
Others in their field
Other Emerging Leaders on “Disease Progression”
- Douglas S. Hawkins · Children'S Hosp Of Philadelphia$157,315,120
- Beth Baseler · Leidos Biomedical Research, Inc.$111,936,677
- Klaus Romero · Critical Path Institute$90,404,592
- Susan Abushakra · Alzheon, Inc.$47,265,244
- John Damon Chodera · Sloan-Kettering Inst Can Research$45,424,821
- Ryan Cirz · Revagenix, Inc.$40,209,479
Research focus
Disease ProgressionDrug TargetingClinical CandidateCollaborationsAnalogDrug KineticsAcute Lymphocytic LeukemiaChildhood Cancer TreatmentAnti-CancerClinical TrialsAnticancer ActivityBirc4 GeneAntineoplastic AgentsCancer CellCancer PatientApoptosisCancer TypeAcute ToxicityBindingCell SurvivalCellular AssayBiochemicalChemotherapyFoundations
Grant awards (3)
Feasibility study of developing SEAK-114 for the treatment of pediatric cancers$399,964
R43 · FY2020 · CA · contact PI
Development of a dual MDM2/XIAP inhibitor with a high therapeutic index for childhood cancers$55,000
R43 · FY2020 · CA · contact PI
Development of a dual MDM2/XIAP inhibitor with a high therapeutic index for childhood cancers$299,823
R43 · FY2019 · CA · contact PI